In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.
Anekpuritanang T, Klairmont MM, Gradowski J, Hagiwara K, Bailey NG, Chandra P, Liu Y, Mulder HL, Easton J, Zhang J, Martin MG, Owczarczyk AB, Dunlap JB, Fan G, Press RD, Raess PW.
Anekpuritanang T, et al. Among authors: klairmont mm.
Blood Adv. 2021 Dec 14;5(23):5057-5059. doi: 10.1182/bloodadvances.2021004983.
Blood Adv. 2021.
PMID: 34559205
Free PMC article.
No abstract available.